12 October 2015 - Basilea Pharmaceutica Ltd. announced today that Health Canada has approved Zevtera (ceftobiprole medocaril) for the treatment of patients 18 years of age and older with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP).

Zevtera is a broad-spectrum antibiotic with bactericidal activity against susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative bacteria associated with pneumonia. Zevtera is not yet launched in Canada.

Prof. Achim Kaufhold, Basilea's Chief Medical Officer, said: "We are very pleased that Zevtera has received regulatory approval in Canada. As a bactericidal cephalosporin with broad-spectrum activity against relevant pathogens causing pneumonia, Zevtera may potentially offer a valuable new treatment option in the empiric treatment setting for life-threatening lung infections."

David Veitch, Basilea's Chief Commercial Officer, stated: "The approval by Health Canada is a significant achievement for Basilea and demonstrates our commitment to expand the availability of Zevtera around the world."

For more details, go to: http://www.basilea.com/News-and-Media/Basilea-announces-that-Health-Canada-approved-ZEVTERA-for-the-treatment-of-bacterial-lung-infections/60ac1f4a-5169-0122-7c39-0fa19fc54c51